SINGAPORE (June 24): Hyphens Pharma International is pursuing a multipronged growth plan. Even as it signs new distribution agreements with other brands, it is developing a steady pipeline of its own products as well. The company’s proprietary product business currently contributes the smallest proportion of revenue. Analysts believe, however, that it still has substantial growth potential.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply